Green Thumb Industries Inc.

OTCPK:GTBI.F Stock Report

Market Cap: US$1.9b

Green Thumb Industries Valuation

Is GTBI.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GTBI.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: GTBI.F ($8.15) is trading below our estimate of fair value ($35.46)

Significantly Below Fair Value: GTBI.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GTBI.F?

Key metric: As GTBI.F is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for GTBI.F. This is calculated by dividing GTBI.F's market cap by their current earnings.
What is GTBI.F's PE Ratio?
PE Ratio30.3x
EarningsUS$63.62m
Market CapUS$1.94b

Price to Earnings Ratio vs Peers

How does GTBI.F's PE Ratio compare to its peers?

The above table shows the PE ratio for GTBI.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.4x
SUPN Supernus Pharmaceuticals
33.7x36.2%US$2.0b
AMPH Amphastar Pharmaceuticals
11.1x5.8%US$1.8b
HRMY Harmony Biosciences Holdings
16.2x29.3%US$2.0b
NDOI Endo
0.5xn/aUS$1.9b
GTBI.F Green Thumb Industries
30.3x35.2%US$2.8b

Price-To-Earnings vs Peers: GTBI.F is expensive based on its Price-To-Earnings Ratio (30.3x) compared to the peer average (15.4x).

Price to Earnings Ratio vs Industry

How does GTBI.F's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

7 CompaniesPrice / EarningsEstimated GrowthMarket Cap
OGN Organon
3x-8.3%US$3.84b
NDOI Endo
0.5xn/aUS$1.87b
KPRX Kiora Pharmaceuticals
1.9x20.7%US$9.90m
CNNC Cannonau
0.2xn/aUS$266.00k
GTBI.F 30.3xIndustry Avg. 16.5xNo. of Companies7PE01224364860+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: GTBI.F is expensive based on its Price-To-Earnings Ratio (30.3x) compared to the US Pharmaceuticals industry average (16.5x).

Price to Earnings Ratio vs Fair Ratio

What is GTBI.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GTBI.F PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio30.3x
Fair PE Ratio31x

Price-To-Earnings vs Fair Ratio: GTBI.F is good value based on its Price-To-Earnings Ratio (30.3x) compared to the estimated Fair Price-To-Earnings Ratio (31x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GTBI.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$8.15
US$16.67
+104.7%
19.3%US$22.34US$12.22n/a8
Dec ’25US$9.29
US$17.23
+85.5%
18.0%US$22.34US$12.22n/a9
Nov ’25US$10.29
US$19.15
+86.1%
16.2%US$25.71US$16.39n/a9
Oct ’25US$10.36
US$19.08
+84.2%
15.4%US$25.71US$16.39n/a10
Sep ’25US$9.69
US$20.62
+112.8%
26.3%US$34.99US$16.39n/a11
Aug ’25US$11.25
US$20.66
+83.7%
26.2%US$34.99US$16.47n/a11
Jul ’25US$11.59
US$20.81
+79.5%
25.7%US$34.99US$16.47n/a11
Jun ’25US$11.40
US$19.85
+74.1%
26.9%US$34.99US$13.26n/a13
May ’25US$13.22
US$19.17
+45.0%
24.4%US$33.33US$13.26n/a13
Apr ’25US$14.83
US$18.40
+24.1%
14.5%US$23.52US$13.26n/a13
Mar ’25US$13.05
US$18.50
+41.9%
17.6%US$26.53US$13.26n/a13
Feb ’25US$13.80
US$17.05
+23.5%
22.7%US$26.21US$10.90n/a13
Jan ’25US$11.29
US$16.52
+46.3%
24.4%US$26.21US$10.90US$8.1713
Dec ’24US$10.54
US$16.49
+56.4%
24.5%US$26.21US$10.90US$9.2913
Nov ’24US$8.23
US$17.29
+110.1%
26.3%US$28.07US$11.16US$10.2911
Oct ’24US$11.12
US$17.38
+56.3%
26.0%US$28.07US$11.16US$10.3611
Sep ’24US$9.50
US$17.29
+82.1%
25.0%US$28.07US$11.16US$9.6912
Aug ’24US$7.11
US$19.13
+169.1%
29.0%US$34.61US$12.52US$11.2512
Jul ’24US$7.62
US$18.66
+144.9%
33.1%US$34.61US$8.14US$11.5913
Jun ’24US$7.40
US$18.19
+145.8%
34.1%US$34.61US$8.14US$11.4012
May ’24US$7.33
US$19.94
+172.0%
42.4%US$44.81US$9.55US$13.2213
Apr ’24US$7.68
US$19.98
+160.0%
40.8%US$44.81US$9.55US$14.8314
Mar ’24US$8.35
US$20.63
+147.1%
37.8%US$44.81US$12.49US$13.0514
Feb ’24US$8.45
US$22.68
+168.4%
34.2%US$44.41US$11.65US$13.8014
Jan ’24US$8.64
US$22.69
+162.6%
34.1%US$44.41US$11.65US$11.2914

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 09:21
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Green Thumb Industries Inc. is covered by 24 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Capital Markets
Russell StanleyBeacon Securities Limited